This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hadziyannis SJ et al. (2004) Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355
Dalgard O et al. (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 160–1265
Sanchez-Tapias JM et al. (2004) Longer treatment duration with peginterferon alfa-2a (40kD) (Pegasys) and ribavirin (Copegus) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC-4 Study [abstract]. Hepatology 40 (Suppl 1): 126A
Acknowledgements
The synopsis was written by Katy Cherry, Assistant Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Research support/grants from Schering-Plough and Roche.
Rights and permissions
About this article
Cite this article
Muir, A. HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon α-2b and ribavirin therapy?. Nat Rev Gastroenterol Hepatol 2, 568–569 (2005). https://doi.org/10.1038/ncpgasthep0337
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0337